ST Pharm (KRX: 237690)
Who is buying ST Pharm?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net bought ₩17.6bn ($13M) of ST Pharm, the 26th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩7.4bn ($6M) and retail investors net sold ₩13.2bn ($10M) over the same window. Foreigners were net buyers on 17 of the 20 sessions.
Foreign investors hold 13.58% of ST Pharm's listed shares (KRX ownership data as of Oct 16, 2026), up from 12.63% twenty sessions earlier and 5.52% a year ago.
The stock closed at ₩91,300 on Oct 16, 2026: +2.82% over 20 sessions, -23.41% year-to-date, -4.10% over one year. The 52-week range is ₩82,100 – ₩172,100.
At ₩91,300 the stock trades at 22.03× 12-month-forward consensus earnings (8 analysts), 21.00× on FY2027 estimates. The trailing P/E published by KRX is 33.74×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩91,300 | +₩4.5bn | +₩1.5bn | ₩-6.0bn |
| 2026-10-15 | ₩83,800 | +₩2.8bn | ₩-0.8bn | ₩-1.9bn |
| 2026-10-14 | ₩85,900 | +₩1.9bn | ₩-2.3bn | +₩0.3bn |
| 2026-10-13 | ₩86,000 | ₩-0.4bn | +₩0.2bn | +₩0.2bn |
| 2026-10-12 | ₩89,000 | +₩0.2bn | ₩-2.0bn | +₩1.7bn |
| 2026-10-08 | ₩92,900 | +₩1.7bn | ₩-3.3bn | +₩1.4bn |
| 2026-10-07 | ₩96,400 | +₩0.1bn | +₩1.1bn | ₩-1.3bn |
| 2026-10-06 | ₩96,900 | +₩1.7bn | +₩1.3bn | ₩-3.0bn |
| 2026-10-02 | ₩93,300 | ₩-2.0bn | ₩-0.5bn | +₩2.5bn |
| 2026-10-01 | ₩95,600 | +₩4.6bn | ₩-0.3bn | ₩-4.3bn |
| 2026-09-30 | ₩91,700 | +₩0.2bn | ₩-0.8bn | +₩0.1bn |
| 2026-09-29 | ₩93,300 | +₩0.3bn | ₩-0.8bn | +₩0.5bn |
| 2026-09-28 | ₩93,100 | +₩1.5bn | +₩1.2bn | ₩-2.8bn |
| 2026-09-23 | ₩91,300 | +₩0.7bn | ₩-0.7bn | +₩0.0bn |
| 2026-09-22 | ₩90,600 | +₩0.8bn | ₩-0.5bn | ₩-0.3bn |
| 2026-09-21 | ₩91,000 | +₩0.8bn | ₩-1.3bn | +₩0.4bn |
| 2026-09-18 | ₩92,700 | ₩-4.0bn | +₩0.0bn | +₩2.0bn |
| 2026-09-17 | ₩91,900 | +₩0.2bn | +₩1.0bn | ₩-1.3bn |
| 2026-09-16 | ₩90,400 | +₩1.0bn | ₩-0.9bn | ₩-0.0bn |
| 2026-09-15 | ₩89,500 | +₩1.1bn | +₩0.3bn | ₩-1.3bn |
| 2026-09-14 | ₩88,800 | +₩1.5bn | ₩-1.7bn | +₩0.2bn |
| 2026-09-11 | ₩90,000 | +₩1.7bn | ₩-2.6bn | +₩0.9bn |
| 2026-09-10 | ₩91,800 | ₩-0.7bn | +₩1.1bn | ₩-0.2bn |
| 2026-09-09 | ₩91,000 | +₩6.9bn | ₩-8.2bn | +₩1.2bn |
| 2026-09-08 | ₩91,900 | +₩5.0bn | ₩-1.9bn | ₩-3.1bn |
| 2026-09-07 | ₩91,700 | ₩-9.1bn | ₩-14.9bn | +₩24.0bn |
| 2026-09-04 | ₩101,200 | +₩0.5bn | ₩-0.2bn | ₩-0.3bn |
| 2026-09-03 | ₩99,000 | +₩0.9bn | ₩-0.9bn | +₩0.1bn |
| 2026-09-02 | ₩101,200 | ₩-0.1bn | ₩-0.5bn | +₩0.7bn |
| 2026-09-01 | ₩103,000 | +₩1.8bn | ₩-2.9bn | +₩0.9bn |
| 2026-08-31 | ₩105,200 | +₩1.8bn | ₩-3.9bn | +₩2.0bn |
| 2026-08-28 | ₩110,200 | ₩-4.9bn | +₩7.3bn | ₩-2.4bn |
| 2026-08-27 | ₩110,900 | +₩3.9bn | +₩0.6bn | ₩-4.1bn |
| 2026-08-26 | ₩110,000 | +₩3.9bn | +₩0.4bn | ₩-4.2bn |
| 2026-08-25 | ₩106,700 | +₩2.6bn | ₩-0.4bn | ₩-2.4bn |
| 2026-08-24 | ₩110,200 | +₩10.3bn | +₩5.1bn | ₩-15.9bn |
| 2026-08-21 | ₩99,700 | ₩-3.7bn | ₩-7.0bn | +₩12.6bn |
| 2026-08-20 | ₩110,900 | ₩-32.5bn | ₩-12.0bn | +₩42.1bn |
| 2026-08-19 | ₩99,300 | +₩1.6bn | ₩-1.9bn | +₩0.4bn |
| 2026-08-18 | ₩100,300 | +₩3.6bn | ₩-4.6bn | +₩1.1bn |
| 2026-08-14 | ₩106,400 | +₩2.6bn | ₩-3.0bn | +₩0.4bn |
| 2026-08-13 | ₩107,600 | +₩0.4bn | ₩-1.4bn | +₩0.9bn |
| 2026-08-12 | ₩107,000 | +₩3.0bn | ₩-3.7bn | +₩0.4bn |
| 2026-08-11 | ₩108,000 | ₩-0.1bn | ₩-0.9bn | +₩0.9bn |
| 2026-08-10 | ₩108,000 | ₩-2.7bn | +₩5.6bn | ₩-2.9bn |
| 2026-08-07 | ₩100,100 | +₩1.1bn | ₩-0.9bn | ₩-0.2bn |
| 2026-08-06 | ₩101,300 | ₩-0.1bn | +₩0.9bn | ₩-0.8bn |
| 2026-08-05 | ₩100,800 | +₩3.0bn | ₩-3.7bn | +₩0.6bn |
| 2026-08-04 | ₩100,700 | +₩2.3bn | +₩0.5bn | ₩-2.9bn |
| 2026-08-03 | ₩94,400 | +₩0.3bn | +₩2.1bn | ₩-2.4bn |
| 2026-07-31 | ₩88,500 | +₩4.1bn | ₩-5.3bn | +₩1.4bn |
| 2026-07-30 | ₩84,700 | +₩3.9bn | ₩-4.9bn | +₩1.5bn |
| 2026-07-29 | ₩90,600 | +₩10.1bn | ₩-8.6bn | +₩0.3bn |
| 2026-07-28 | ₩98,500 | +₩6.4bn | ₩-1.1bn | ₩-3.7bn |
| 2026-07-27 | ₩99,900 | ₩-11.9bn | +₩0.4bn | +₩11.4bn |
| 2026-07-24 | ₩116,700 | +₩0.9bn | ₩-0.6bn | ₩-0.3bn |
| 2026-07-23 | ₩117,900 | +₩1.2bn | +₩0.7bn | ₩-1.9bn |
| 2026-07-22 | ₩113,000 | +₩1.6bn | ₩-2.1bn | +₩0.4bn |
| 2026-07-21 | ₩114,000 | +₩2.5bn | ₩-1.6bn | ₩-0.9bn |
| 2026-07-20 | ₩113,900 | +₩0.4bn | ₩-1.2bn | ₩-0.2bn |
| 2026-07-16 | ₩124,300 | ₩-0.2bn | +₩2.7bn | ₩-3.6bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩4.5bn | +$3M | +₩1.5bn | ₩-6.0bn |
| 5 days | +₩8.9bn | +$7M | ₩-3.4bn | ₩-5.7bn |
| 20 days | +₩17.6bn | +$13M | ₩-7.4bn | ₩-13.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying ST Pharm stock?
Over the last 5 sessions foreign investors net bought ₩8.9bn ($7M) of ST Pharm; over 60 sessions they net bought ₩41.4bn ($31M); since Jan 1, 2026 they net bought ₩66.2bn ($49M). Over 20 sessions the stock is the 26th largest foreign net purchase among 1828 KOSDAQ stocks.
How much of ST Pharm do foreign investors own?
Foreign investors own 13.58% of ST Pharm's shares as of Oct 16, 2026, versus 5.52% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩7.4bn ($6M) and retail investors net sold ₩13.2bn ($10M) of ST Pharm. Foreign buying is being met mainly by retail selling.
Is ST Pharm listed on KOSPI or KOSDAQ?
ST Pharm (에스티팜) trades on KOSDAQ under KRX code 237690 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩285bn ($212M) | – | ₩34bn ($25M) | ₩18bn ($13M) |
| 2024 | ₩274bn ($203M) | -3.90% | ₩28bn ($21M) | ₩32bn ($24M) |
| 2025 | ₩332bn ($246M) | +21.20% | ₩55bn ($41M) | ₩55bn ($41M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.